Oral Contraceptive and Glioma Risk: A Prospective Cohort Study and Meta-Analysis

Chuan Shao 1,2,3, Hui Tang 2, Xiaoya Wang 2, Jiaquan He 2, Pan Wang * and Nan Wu *

1 Department of Neurosurgery, Chongqing General Hospital, Chongqing, China, 2 Department of Neurosurgery, Nanchong Central Hospital, The Second Clinical Medical College, North Sichuan Medical College, Nanchong, China, 3 Graduate Institute, Chongqing Medical University, Chongqing, China

Background: Epidemiological evidence that glioma has a slight male predominance implies that factors associated with sex hormones may play a role in the development of glioma. The association between oral contraceptive (OC) use and glioma risk remains controversial.

Method: In the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial of 70,516 women in the USA, Cox proportional hazards regression analyses were adopted to calculate the crude and adjusted hazard ratios (HRs) and 95% confidence intervals (CIs). Additionally, a meta-analysis combining the PLCO findings with those of other prospective cohorts was performed.

Results: During a mean follow-up of ∼11.7 years, 110 of 70,516 women aged 50–78 years at baseline were diagnosed with glioma in PLCO studies. Compared with never users, an inverse association of borderline significance was found for OC users (HR 0.67, 95% CI 0.44–1.04, P = 0.074). Analyses assessing glioma risk according to the duration of OC use yielded no significant association. When PLCO was combined with four other prospective studies, there was an inverse association between OC use and glioma risk (HR 0.85, 95% CI 0.75–0.97, I 2 = 0.0%). Further dose-response analysis showed a nonlinear, inverse relationship between OC use and glioma risk (P < 0.001).

Conclusions: This study provided some evidence of a nonlinear, inverse association between OC use and glioma risk. Future larger studies are warranted to validate this finding.

Keywords: oral contraceptive, glioma, risk factors, cohort, meta-analysis

INTRODUCTION

Glioma is the most aggressive and most common brain malignancy and mainly comprises ependymoma, oligodendroglioma, astrocytoma, and oligoastrocytoma (1). The causative factors, apart from a strong link with ionizing radiation, remain largely unknown (2). Previous studies have suggested possible links between personal exposure and lifestyle and the development of glioma, but few well-established relationships have been identified (3).
Epidemiological studies have shown that the incidence of glioma, always exhibits sex disparity, with a 40%–50% lower incidence in women than in men (2). Experimental studies have shown the presence of progesterone and estrogen receptors in astrocytomas, and that metabolites of estradiol have a strong antiproliferative effect on glioma and induce an increase in apoptosis of human glioma cell lines (4, 5). These observations indicate that factors related to sex steroid hormones may play a role in the pathogenesis of glioma.

Oral contraception (OC) is a widely used, safe, and effective method to control birth, reduce menstrual symptoms, and regulate irregular or heavy menstruation (6, 7). Thus, additional estrogen and progestin exposures were present in women, and concerns about the risks or benefits of OC use were aroused. Researches on the effects of OC use on glioma risk have shown inconsistent findings (8–21). Notably, most previous studies were mainly retrospective case-control studies, and thus selection and recall bias may have distorted the findings. To strengthen the understanding of the possible effects of the OC on glioma risk, we assessed the association between OC and glioma risk in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial with a prospective design. We also performed a meta-analysis combining the PLCO with published prospective studies.

METHODS
Data Sources
The PLCO study was a randomized controlled cancer screening trial. Detailed information about the rationale and design has been reported previously (22). A total of 154,887 subjects were recruited from 10 centers across the United States between 1993 and 2001. All eligible participants provided written informed consent and completed a self-reported baseline questionnaire, which mainly included information on demographics, body size (i.e., height, and weight), personal and family history of disease, smoking history, exogenous hormone use (in women), reproductive factors (in women), and prostate-related factors (in men). Ethical approval was obtained from the ethics committees of all PLCO cancer centers. The project number of the current study is PLCO-712.

Study Population
Figure 1 illustrates the flow chart of identifying subjects. At enrollment into the PLCO study, 78,209 of 154,887 subjects were women. According to our study design, we further excluded 7,693 subjects as they failed to return the baseline questionnaire (n = 2,094), had a history of glioma or other cancers (n = 5,199), and unavailable data about follow-up time (n = 277) or OC exposure (n = 123) was reported. Thus, data on 70,516 women aged 50–78 years at baseline were eligible for our analysis.

Case Ascertainment
An annual follow-up questionnaire on cancer diagnosis was completed by all participants or their proxies. If someone was diagnosed with glioma, more information on diagnosis date, clinic or hospital center, and the doctor’s contact information were identified. All glioma cases were verified through medical records. Follow-up was censored when participants died, participants were diagnosed with glioma, participants withdrew from the trial, or the trial ended (December 31, 2009), whichever occurred first.

Exposure Assessment
Data about exogenous hormone use was retrospectively collected by a self-reported questionnaire at baseline. All female subjects were asked whether they had ever used OC and hormone replacement therapy (HRT), age at first use, and years of use in the baseline questionnaire. Information on the type of hormone was not collected. We performed an analysis for ever use and duration of ever use (<5 vs. 6–9 vs. ≥10 years) compared with never use of OC.

Statistical Analyses
Differences in baseline characteristics between OC users and nonusers were analyzed using χ² tests for categorical variables. Cox proportional hazards regression analyses were adopted to calculate the crude and adjusted hazard ratios (HRs) and 95% confidence intervals (CIs). The following covariates, including age (smooth), race (White, non-Hispanic vs. other/unknown), marital status (married or living as married vs. never married), education (up to high school vs. some college or post-high school training vs. at least college graduate), smoking status (never vs. ever smoked), HRT (ever vs. never use), and body mass index (BMI; <25 kg/m² vs. ≥25 kg/m²) were assessed in the adjusted model. Subgroup analysis was performed according to the BMI and HRT use. All analyses were performed by R software (version 3.4.3; http://www.R-project.org) and Empower (version 2.0; X&Y Solutions, Inc. Boston, MA, USA).

Meta-Analysis
To retrieve studies on the relationship between OC use and glioma risk, we performed a literature search of PubMed and EMBASE databases (from their inception to Jan. 22, 2022). The detailed search string was: [hormone (Title/Abstract) OR contraceptive (Title/Abstract)] AND [“brain tumor” (Title/Abstract) OR “brain cancer” (Title/Abstract) OR “brain neoplasms” OR glioma (Title/Abstract)]. Other than limiting to human studies, no other limits were imposed. We also reviewed the reference lists of potential studies, reviews, and meta-analyses associated with this topic. Prospective cohort studies providing adjusted HRs with 95% CIs (or other data about exposure distribution to calculate them) were considered to be eligible for meta-analysis. Two reviewers independently and carefully extracted the following data: first author, publication year, study country, study design, study period, sample size, exposure variables, the most fully adjusted risk estimates with 95% CIs, and adjustment factors. Any disagreements were settled by discussion. The quality assessment of all eligible studies was performed through the Newcastle–Ottawa Scale (http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp, accessed on 13 June 2022). The scoring system includes selection (a maximum of four stars), comparability (a maximum of two
stars), and outcome (a maximum of three stars). In this study, we also made some modifications to this guideline tool, including the following aspects: (1) a maximum of one star was awarded to a study in which adjusted risk estimates were reported, as confounding factors are one of the most biggest concerns in observational studies; and (2) a study with follow-up (greater than the median or mean follow-up of 5 years) was awarded one star.

We combined the risk estimates with corresponding 95% CIs with a random-effects model by DerSimonian and Laird (23), when the value of $I^2$ statistic was $>$50% (24); otherwise, a fixed-effects model was adopted. Potential publication bias was evaluated by Begg’s funnel plots and Egger’s test, while publication bias was not evaluated when there were $<$10 included studies. We also assessed the influence of single studies by excluding one study at a time. As the most frequent definition of OC exposure was users vs. nonusers, we first performed an analysis of comparison of OC users vs. nonusers. When some studies only provided risk estimates for current use and past use vs. no use, we finished data conversion representing ever use vs. no use as described previously (25, 26). Briefly, we pooled the risk estimates using a fixed-effects model before combining with other studies. To determine the causality of an association, we tried to identify a dose-response relationship between OC use and glioma with a one-stage robust error meta-regression model proposed by Doi (27). This method treats each study as a cluster and weighs the effects of each study by its inverse variance, while employs the robust-variance to address the potential correlation of the within-study effects. Also, it requires at least two categories for each included study. When a specific exposure level was reported as a range, the median or mean was assigned. When the highest or lowest exposure level was open-ended, its width matching the interval of the adjacent category was assumed. All analyses for meta-analysis were performed using STATA software (version 15.0, STATA Corp., College Station, TX, USA).

RESULTS

PLCO Trial
A total of 70,516 women aged 50–78 years at baseline were eligible for our analysis. Of these, 110 women were diagnosed with incident glioma during a mean follow-up of $\sim$11.7 years. Baseline cohort characteristics are shown in Table 1. Most participants were younger than 65 years and were White, non-Hispanic. Women with HRT use were more likely to be OC users. Prior to adjustment for any potential confounders, ever OC use was inversely associated with risk of glioma (HR 0.63, 95% CI 0.43–0.94), and some borderline significant results were observed for the duration of OC use (Table 2). Similarly, an inverse association of borderline significance was found for ever users in the multivariable analysis. Further analyses assessing glioma risk according to the duration of OC use yielded no significant association between OC and glioma risk (Table 2).

Table 3 shows the subgroup results according to BMI. The association between OC use and glioma risk was more pronounced in women with BMI $\geq$25 kg/m$^2$ (adjusted HR 0.46,
### TABLE 1 | Baseline participant characteristics according to OC use in the PLCO trail.

| Characteristic* | OC use | P-value |
|-----------------|--------|---------|
|                 | Never use (n = 32,206) | Ever user (n = 38,310) |
| Age (years), n (%) | | |
| <65 | 15,493 (48.11%) | 30,156 (78.72%) | <0.001 |
| ≥65 | 16,713 (51.89%) | 8,154 (21.28%) |
| Arm, n (%) | | | 0.125 |
| Intervention | 16,237 (50.42%) | 19,092 (49.84%) |
| Control | 15,969 (49.58%) | 19,218 (50.16%) |
| Race, n (%) | | | <0.001 |
| White, non-Hispanic | 28,068 (87.15%) | 34,325 (89.60%) |
| Others/unknown | 4,138 (12.85%) | 3,985 (10.40%) |
| Education, n (%) | | | <0.001 |
| Up to high school | 12,522 (38.97%) | 11,584 (30.29%) | <0.001 |
| Some college or post high school training | 11,004 (34.25%) | 14,332 (37.47%) |
| At least college graduate | 8,607 (26.79%) | 12,329 (32.24%) |
| Marital status, n (%) | | | <0.001 |
| Married or living as married | 30,511 (94.90%) | 37,552 (98.15%) |
| Never married | 1,641 (5.10%) | 706 (1.85%) |
| Smoking status, n (%) | | | <0.001 |
| Never | 19,643 (61.00%) | 19,879 (51.89%) |
| Ever | 12,558 (39.00%) | 18,430 (48.11%) |
| BMI (kg/m²), n (%) | | | 0.004 |
| <25 | 12,855 (40.55%) | 15,769 (41.64%) |
| ≥25 | 18,845 (59.45%) | 22,099 (58.36%) |
| HRT, n (%) | | | <0.001 |
| Never | 13,170 (41.14%) | 9,865 (25.85%) | 0.67 (0.44, 1.04) | 0.07 |
| Ever | 18,841 (58.86%) | 28,295 (74.15%) | 0.56 (0.26, 1.19) | 0.131 |

OC, oral contraception; PLCO, prostate, lung, colorectal and ovarian; BMI, body mass index; HRT, hormone replacement therapy; n, number.
* There were 138, 106, 948, 6, and 345 subjects with missing data for education, marital status, BMI, smoking status, and HRT use, respectively.

### TABLE 2 | OC use and glioma risk in the PLCO trail.

| Exposure | Cohort (n) | Cases (n) | Non-adjusted HR (95% CI) and P-value | Adjusted HR (95% CI) and P-value |
|----------|------------|-----------|--------------------------------------|----------------------------------|
| OC use   |            |           |                                      |                                  |
| Never    | 32,206     | 58        | 1.0                                  | 1.0                              |
| Ever     | 38,310     | 42        | 0.63 (0.43, 0.94) 0.025              | 0.67 (0.44, 1.04) 0.074          |
| Years of OC |          |           |                                      |                                  |
| Never    | 32,206     | 58        | 1.0                                  | 1.0                              |
| ≤5       | 23,087     | 25        | 0.63 (0.39, 1.00) 0.051              | 0.66 (0.40, 1.09) 0.104          |
| 6–9      | 6,307      | 9         | 0.82 (0.41, 1.67) 0.591              | 0.91 (0.44, 1.88) 0.798          |
| ≥10      | 8,841      | 8         | 0.52 (0.25, 1.10) 0.086              | 0.56 (0.26, 1.19) 0.131          |

PLCO, prostate, lung, colorectal and ovarian; HR, hazard ratio; 95% CI, 95% confidence interval; OC, oral contraception; HRT, hormone replacement therapy; BMI, body mass index; n, number.

Adjusted for age (smooth), race, marital status, education, BMI, HRT, and smoking.

595 CI 0.25–0.83), but not with BMI<25 kg/m² (adjusted HR 1.11, 95% CI 0.58–2.15). When assessing the duration of OC use, no clear dose-response relationship was identified. Another subgroup analysis by HRT use showed no significant difference between ever users and never users of HRT, although none of the risk estimates was significant (Table 4).

### Meta-Analysis

The process of study selection is shown in Figure 2. The initial literature search of PubMed (n = 417) and EMBASE (n = 551) databases identified 968 records. After careful review, four studies met the inclusion criteria (18–21), and including PLCO, five were accepted for analysis. The basic characteristics of included
Shao et al. Oral Contraceptive and Glioma

TABLE 3 | OC use and glioma risk according to BMI in the PLCO trial.

| Exposure | 
|----------|-------------------------------|-------------------------------|
|          | BMI <25 kg/m² | BMI ≥25 kg/m² |
|          | Crude HR (95% CI) and P-value | Adjusted HR (95% CI) and P-value |
|          | Crude HR (95% CI) and P-value | Adjusted HR (95% CI) and P-value |
| OC use   | | |
| Never use | 1.0 | 1.0 |
| Ever use  | 0.98 (0.53, 1.82) 0.954 | 0.43 (0.25, 0.75) 0.003 |
|          | | 0.46 (0.25, 0.83) 0.010 |
| Years of OC use | | |
| Never use | 1.0 | 1.0 |
| ≤5 | 0.84 (0.40, 1.76) 0.636 | 0.48 (0.26, 0.91) 0.023 |
| 6–9 | 1.62 (0.65, 4.06) 0.304 | 0.42 (0.13, 1.35) 0.144 |
| ≥10 | 0.91 (0.34, 2.45) 0.855 | 0.31 (0.10, 1.00) 0.050 |

PLCO, prostate, lung, colorectal and ovarian; HR, hazard ratio; 95% CI, 95% confidence interval; OC, oral contraception; HRT, hormone replacement therapy; BMI, body mass index.

TABLE 4 | OC use and glioma risk according to HRT in the PLCO trial.

| Exposure | Nonusers | Ever users |
|----------|-----------|------------|
|          | Crude HR (95% CI) and P-value | Adjusted HR (95% CI) and P-value |
|          | Crude HR (95% CI) and P-value | Adjusted HR (95% CI) and P-value |
| OC use   | | |
| Never use | 1.0 | 1.0 |
| Ever use  | 0.49 (0.22, 1.11) 0.087 | 0.66 (0.42, 1.06) 0.089 |
|          | 0.54 (0.23, 1.28) 0.151 | 0.73 (0.44, 1.22) 0.228 |
| Years of OC use | | |
| Never use | 1.0 | 1.0 |
| ≤5 | 0.39 (0.13, 1.13) 0.083 | 0.69 (0.40, 1.19) 0.184 |
| 6–9 | 0.39 (0.05, 2.93) 0.358 | 0.94 (0.43, 2.01) 0.864 |
| ≥10 | 0.89 (0.27, 2.98) 0.851 | 0.41 (0.16, 1.04) 0.061 |

PLCO, prostate, lung, colorectal and ovarian; HR, hazard ratio; 95% CI, 95% confidence interval; OC, oral contraception; HRT, hormone replacement therapy; BMI, body mass index.

studies were shown in Supplementary Table 1. These studies were conducted in the USA, Sweden, Denmark, Canada, the UK, Germany, Netherlands, Greece, Italy, Norway, and Spain. At baseline, women aged 20–80 years were recruited. More than 90% women were White, non-Hispanic in the NIH-AARP Diet and Health Study (21), while no detailed proportion was reported in other studies (18–20). The mean follow-up time ranged from 6.2 to 11.6 years. A total of 1,263 gliomas were diagnosed. Glioma cases were ascertained by cancer registrations, health insurance records, national mortality databases, or pathology registries. OC exposure was assessed by a self-administered/reported questionnaire. All included studies reported nonusers of OC as the reference category. The highest exposure category ranged from more than 3 to 15 years. All studies were awarded seven stars, indicating that the included studies were of high quality (Supplementary Table 2).

Figure 3 shows the forest plot for the effect of OC use on glioma risk. The pooled results gave a decreased risk of 0.85 with OC users compared with nonusers (95% CI 0.75–0.97, \( I^2 = 0.0\)). Further analysis showed that the overall results were not influenced by a single study, indicating that the results were stable (Supplementary Table 3). Dose-response analysis showed a nearly “U” shaped association between glioma risk and OC use (Figure 4, \( P \) for nonlinearity <0.001). Specifically, the strongest inverse relationship was found in women who took the OC pills for 4–5 years. There was no further reduction in glioma risk with increasing duration of OC use over 4–5 years.

DISCUSSION

In the PLCO study, we found that the use of OC was not significantly associated with glioma risk. In the subsequent meta-analysis that incorporated our study, we found there was an inverse association between glioma risk and OC use. In line with PLCO, nearly all previous studies showed a weak inverse association or no significant association between OC use and glioma risk. However, the relationship between OC use and glioma risk has been reported with inconsistent results (8–21). Further analysis showed a nearly “U” shaped association between glioma risk and OC use.
Glioma risk, except one reporting an increased risk of glioma with OC use (17). To the best of our knowledge, we first reported that BMI was as an effect modifier on the association between glioma risk and OC use. The association between OC use and glioma risk was more pronounced in women with BMI $\geq 25$ kg/m$^2$. However, there was a positive association between glioma risk and OC use, albeit insignificant. One potential explanation is that this discrepancy was associated with additional estrogen exposure in overweight women. Excess adipose tissue can cause increased production of estrogen through higher conversion rates of androgens due to increased aromatase activity, which results in higher aromatization of androstenedione (28–31). Another explanation is that the subgroup results were chance findings.

Other than our study, only two case-control studies examined the potential interaction between postmenopausal hormone use
and OC use (13, 16). In the large San Francisco Bay Area Adult Glioma Study with 619 cases and 650 controls, Felini et al. found that exogenous hormone use was inversely associated with glioma risk, but there was no evidence of antagonism or synergy effect between previous OC use and HRT and glioma (13). We also found that HRT did not modify the association between glioma risk and OC use. On the contrary, another study showed that users of both OC and HRT were less likely to have glioma (16), compared to those with neither OC nor HRT use (16).

Currently, the components of OC tablets differ markedly from those used previously. When the OCs entered the market in the 1960s, estrogen concentration in earlier generations was >100 µg (32). Today, the OCs contain lower levels of estrogen (<35 µg) and progestin (32). There is some evidence that the expression of estrogen and progesterone receptors varies in glioma, and for example, higher-grade glioma is associated with lower expression of estrogen receptors and higher expression of progesterone receptors (4). Also in vitro studies, a dual role of progesterone in glioblastoma cells has been suggested: physiological concentrations increase cell proliferation, invasion, and migration, while higher doses beyond the physiological level inhibit cell proliferation and promote cell death (33). To our knowledge, only one case-control study based on the nationwide prescription registry assessed the effect of hormonal contraceptive components on glioma risk (17). The positive association between glioma risk and long-term use of hormonal contraceptive was most pronounced for progestogen-only therapy (17). Hence, women with different hormone exposure may also bear a different risk of glioma and more studies are needed to clarify this issue.

Another concern is the association between the state of OC use and glioma risk. Three studies provided limited data for current use vs. past/former use of OC. One prospective European investigation with 276,212 individuals reported no significant difference between past and current OC users (20). Another case-control study reported no association among past users, but a significant inverse association among current users (13). Additionally, a more obvious dose–response trend of decreasing risk with a longer duration of use was identified among current users (13). On the contrary, the national prescription registry case-control study showed that the increased risk was higher for current/recent use rather than for past users (17). These findings indicate that the risk may not change over time after OC discontinuation. Therefore, caution is warranted regarding the findings and ongoing discussion about the duration of OC use and glioma risk is needed.

Several meta-analyses on the association between OC and glioma risk have been published (34–37). Similarly, these results were mainly based on retrospective studies and showed a preventive effect of OC on glioma risk. The latest meta-analysis of eight retrospective case-control and four prospective cohort studies published in 2021 showed a nonlinear correlation between glioma risk and duration of OCs use (37). Specifically, significant benefits of a decreased risk of glioma were observed in women with longer-term OC use, with a “time window” of over 7.5 years (37). In the current study, we pooled the PLCO and other prospective cohort studies and found a nearly “U” shaped association between OC and glioma risk. The strongest inverse association was found in women who took the OC pills for 4–5 years and when using OC pills more than 4–5 years, the risk of glioma does not decrease further.

Advantages of the PLCO study included its prospective design, longer duration of follow-up, and consideration of some essential confounders. Several limitations should be mentioned as well. First, there were small numbers of glioma cases in the PLCO trial and meta-analysis, which may have led to chance results for OC use. Concerning that little is known about the etiology, this study provided some insight into the role of female hormone on glioma risk. Second, all self-reported exposures at baseline always have bias concerns; thus, measurement error or misclassification may be inevitable. Third, uncontrolled confounders may belie the true association between OC use and glioma risk. Finally, the potential publication bias was not addressed, as few studies were included in this meta-analysis.

In conclusion, our study provided some evidence of an inverse association between OC use and glioma risk. Additional prospective studies with a large sample size are warranted to confirm our findings, especially addressing the components of OC and the dose-response relationship.

**DATA AVAILABILITY STATEMENT**

The data of the current study are available from the NIH PLCO study group subject to restrictions, as the data were used under
license for the current study. Requests to access the datasets should be directed at: https://cdas.cancer.gov/plco/.

**ETHICS STATEMENT**

Ethical approval was obtained from the Ethics Committees of all PLCO cancer centers. The patients/participants provided their written informed consent to participate in PLCO study at study entry.

**AUTHOR CONTRIBUTIONS**

CS, HT, and XW contributed to conception and design of the study. CS, HT, XW, and PW performed data cleaning and statistical analysis. CS, HT, XW, PW, NW, and JH wrote the first draft of the manuscript. PW and NW funding acquisition. All authors contributed to manuscript revision, read, and approved the submitted version.

**ACKNOWLEDGMENTS**

The authors thank the NCI for access to its data collected by the PLCO Cancer Screening Trial. The statements contained herein are solely those of the author and do not represent or imply concurrence or endorsement by the NCI.

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fpubh.2022.878233/full#supplementary-material

**REFERENCES**

1. Ostrom QT, Patil N, Cioffi G, Waite K, Kruchko C, Barnholtz-Sloan JS. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2013-2017. *Neuro Oncol*. (2020) 24:v1–96. doi: 10.1093/neuonc/noa200

2. Ostrom QT, Barnholtz-Sloan JS. Current state of our knowledge on brain tumor epidemiology. *Carr Neurol Neurosci Rep*. (2011) 11:329–35. doi: 10.1007/s11910-011-0189-8

3. Kuan AS, Green J, Kitahara CM, Berrington De González A, Key TK, et al. Diet and risk of glioma: combined analysis of 3 large prospective studies in the UK and USA. *Neuro Oncol*. (2019) 21:944–52. doi: 10.1093/neuonc/noz013

4. Tavares CR, Gomes-Braga FD, Costa-Silva DR, Escórcio-Dourado CS, Borges US, Conde-Junior AM, et al. Expression of estrogen and progesterone receptors in astrocytomas: a literature review. *Clinics*. (2016) 71:481–6. doi: 10.6061/clinics.2016(08)12

5. Hirtz A, Rech F, Dubois-Pot-Schneider H, Dumond H. Astrocytoma: a hormone-sensitive tumor? *Int J Mol Sci*. (2020) 21:9114. doi: 10.3390/ijms21239114

6. de Wit AE, Boon SH, Giloy EJ, Joffe H, Schoevers RA, Oldehinkel AJ. Association of use of oral contraceptives with depressive symptoms among adolescents and young women. *JAMA Psychiatry*. (2020) 77:52–9. doi: 10.1001/jamapsychiatry.2019.2838

7. Franceschini G, Di Leone A, D’Archi S, Masetti R. Oral contraceptives and breast cancer risk: an underestimated risk? *Crit Rev Oncol Hematol*. (2020) 147:102876. doi: 10.1016/j.critrevonc.2020.102876

8. Hochberg F, Toniole P, Cole P, Salzman M. Nonoccupational risk indicators of glioblastoma in adults. *J Neurooncol*. (1996) 30:55–60. doi: 10.1007/BF00182087

9. Huang K, Whelan EA, Ruder AM, Ward EM, Deddens JA, Davis-King KE, et al. Reproductive factors and risk of glioma in women. *Cancer Epidemiol Biomarkers Prev*. (2004) 13:1583–8. doi: 10.1158/1055-9965.1583.13.10

10. Hatch EE, Linet MS, Zhang J, Fine HA, Shapiro WR, Selker RG, et al. Reproductive and hormonal factors and risk of brain tumors in adult females. *Int J Cancer*. (2005) 114:797–805. doi: 10.1002/ijc.20776

11. Wigertz A, Sjöstrand G. Mathematical, T. Ahlbom A, Hall F, Fychting M, et al. Risk of brain tumors associated with exposure to exogenous female sex hormones. *Am J Epidemiol*. (2006) 164:629–36. doi: 10.1093/aje/kwj234

12. Wigertz A, Lönner S, Hall F, Auvinen A, Christensen HC, Johannessen C, et al. Reproductive factors and risk of meningioma and glioma. *Cancer Epidemiol Biomarkers Prev*. (2008) 17:2663–70. doi: 10.1158/1055-9965.EPI-08-0406

13. Felini MJ, Olshan AE, Schroeder JC, Carozza SE, Miike R, Rice T, et al. Reproductive factors and hormone use and risk of adult gliomas. *Cancer Causes Control*. (2009) 20:87–96. doi: 10.1007/s10552-008-9220-z

14. Wang SS, Hartge P, Yeager M, Carreon T, Ruder AM, Linet M, et al. Joint associations between genetic variants and reproductive factors in glioma risk among women. *Am J Epidemiol*. (2011) 174:901–8. doi: 10.1093/aje/kwr184

15. Anic GM, Madden MH, Nabors LB, Olson JJ, LaRocca RV, Thompson ZJ, et al. Reproductive factors and risk of primary brain tumors in women. *J Neurooncol*. (2011) 104:297–304. doi: 10.1007/s11060-011-0247-0

16. Krishnamachari B, Ilyasova D, Scheurer ME, Bondy ML, Wrensch M, Davis FG. A pooled multisite analysis of the effects of female reproductive hormones on glioma risk. *Cancer Causes Control*. (2014) 25:1007–13. doi: 10.1007/s10552-014-0400-8

17. Andersen L, Friis S, Hallas J, Ravn P, Kristensen BW, Gaist D. Hormonal contraceptive use and risk of glioma among younger women: a nationwide case-control study. *Br J Clin Pharmacol*. (2015) 79:67–84. doi: 10.1111/bcp.12535

18. Silvera SA, Miller AB, Rohan TE. Hormonal and reproductive factors and risk of glioma: a prospective cohort study. *Int J Cancer*. (2006) 118:1321–4. doi: 10.1002/ijc.21467

19. Benson VS, Pirie K, Green J, Casabonne D, Beral V, Million Women Study Collaborators. Lifestyle factors and primary glioma and meningioma tumours in the Million Women Study cohort. *Br J Cancer*. (2008) 99:185–90. doi: 10.1038/sj.bjc.6604445

20. Michaud DS, Gallo V, Schlehofer B, Tjønneland A, Olsen A, Overvad K, et al. Reproductive factors and exogenous hormone use in relation to risk of glioma and meningioma in a large European cohort study. *Cancer Epidemiol Biomarkers Prev*. (2010) 19:2562–9. doi: 10.1158/1055-9965.EPI-10-0447

21. Kabat GC, Park Y, Hollenbeck AR, Schatzkin A, Rohan TE. Reproductive factors and exogenous hormone use and risk of adult glioma in women in the NIH-AARP Diet and Health Study. *Int J Cancer*. (2011) 128:944–50. doi: 10.1002/ijc.25413

22. Prorok PC, Andriole GL, Bresalier RS, Buys SS, Chia D, Crawford ED, et al. Design of the prostate, lung, colorectal and Ovarian (PLCO) Cancer screening trial. *Control Clin Trials*. (2000) 21:2735–3095. doi: 10.1016/S0197-2456(00)00098-2

23. DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials*. (1986) 7:177–88. doi: 10.1016/0197-2456(86)90046-2

24. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *Br Med J*. (2003) 327:557–60. doi: 10.1136/bmj.327.7443.557

25. Dong JY, Zhang YH, Qin LQ. Erectile dysfunction and risk of cardiovascular disease: meta-analysis of prospective cohort studies. *J Am Coll Cardiol*. (2011) 58:1378–85. doi: 10.1016/j.jacc.2011.06.024

26. Manzoli L, Villari P, Pirone GM, Boccia A. Marital status and mortality in the elderly: a systematic review and meta-analysis. *Soc Sci Med*. (2007) 64:77–94. doi: 10.1016/j.socscimed.2006.08.031
27. Xu C, Doi SAR. The robust error meta-regression method for dose-response meta-analysis. *Int J Evid Based Healthc.* (2018) 16:138–44. doi: 10.1097/XEB.0000000000000132

28. Roberts DL, Dive C, Renehan AG. Biological mechanisms linking obesity and cancer risk: new perspectives. *Annu Rev Med.* (2010) 61:301–16. doi: 10.1146/annurev.med.080708.082713

29. Ferguson RD, Gallagher EJ, Scheiman R, LeRoith D. The epidemiology and molecular mechanisms linking obesity, diabetes, and cancer. *Vitam Horm.* (2013) 93:51–98. doi: 10.1016/B978-0-12-416673-8.00010-1

30. Talmor A, Dunphy B. Female obesity and infertility. *Best Pract Res Clin Obstet Gynaecol.* (2015) 29:498–506. doi: 10.1016/j.bpobgyn.2014.10.014

31. Avgerinos K, Spyrou N, Mantzoros CS, Dalamaga M. Obesity and cancer risk: Emerging biological mechanisms and perspectives. *Metabolism.* (2019) 92:121–35. doi: 10.1016/j.metabol.2018.11.001

32. Burkman R, Bell C, Serfaty D. The evolution of combined oral contraception: improving the risk-to-benefit ratio. *Contraception.* (2011) 84:19–34. doi: 10.1016/j.contraception.2010.11.004

33. Bello-Alvarez C, Camacho-Arroyo I. Impact of sex in the prevalence and progression of glioblastomas: the role of gonadal steroid hormones. *Biol Sex Differ.* (2021) 12:28. doi: 10.1186/s13293-021-00372-5

34. Qi ZY, Shao C, Zhang X, Hui GZ, Wang Z. Exogenous and endogenous hormones in relation to glioma in women: a meta-analysis of 11 case-control studies. *PLoS ONE.* (2013) 8:e68695. doi: 10.1371/journal.pone.0068695

35. Zong H, Xu H, Geng Z, Ma C, Ming X, Shang M, et al. Reproductive factors in relation to risk of brain tumors in women: an updated meta-analysis of 27 independent studies. *Tumour Biol.* (2014) 35:11579–86. doi: 10.1007/s13277-014-2448-1

36. Lan YL, Wang X, Lou JC, Ma BB, Xing JS, Zou S, et al. Update on the effect of exogenous hormone use on glioma risk in women: a meta-analysis of case-control and cohort studies. *J Neurooncol.* (2018) 137:357–65. doi: 10.1007/s11060-017-2725-0

37. Yang X, Liu F, Zheng J, Cheng W, Zhao C, Di J. Relationship between oral contraceptives and the risk of gliomas and meningiomas: a dose-response meta-analysis and systematic review. *World Neurosurg.* (2021) 147:e148–62. doi: 10.1016/j.wneu.2020.11.175

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Shao, Tang, Wang, He, Wang and Wu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.